Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01802515 · ClinicalTrials.gov registry record · NA
A Drug Treatment for Cocaine Users Who Are Also on Methadone Maintenance Treatment
A NA study, sponsored by Yale University.
- Terminated
- Registry status
- NA
- Development phase
- 14
- Enrollment target
NCT01802515: Clinical Trial NA study, sponsored by Yale University.
NCT01802515 is a NA study that was terminated before completion, run by Yale University. The registered enrollment target is 14 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01802515, a NA study, was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
Study Summary
The main goal of this study is to evaluate the safety and tolerability of 40 or 80 mg atomoxetine as a treatment for cocaine dependence. The Phase I studies summarized above support the safety of atomoxetine in combination with stimulants. As the next step, the investigators will evaluate the safety and tolerability of atomoxetine in a small clinical trial with cocaine users. If atomoxetine is found to be promising in this study and sufficiently powered, double-blind, placebo-controlled studies will be proposed.
Primary Outcome
The number of participants completing all 8 weeks of treatment phase.
Interventions
- DRUG Placebo
- DRUG Atomoxetine, low dose
- DRUG Atomoxetine, high dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2012-12 |
| Est. Completion | 2014-03 |
| Phase | NA |
Why NCT01802515 stopped before completion
NCT01802515 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01802515 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01802515 about?
NCT01802515 is a clinical study titled "A Drug Treatment for Cocaine Users Who Are Also on Methadone Maintenance Treatment". The main goal of this study is to evaluate the safety and tolerability of 40 or 80 mg atomoxetine as a treatment for cocaine dependence. The Phase I studies summarized above support the safety of atomoxetine in combination with stimulants. As the next step, the investigators will evaluate the safety...
What is the current status of trial NCT01802515?
This trial is currently terminated. It is a NA study. The enrollment target is 14 participants. The study started on 2012-12. Estimated completion is 2014-03.
What interventions are being tested in trial NCT01802515?
The interventions under investigation include: Placebo (DRUG), Atomoxetine, low dose (DRUG), Atomoxetine, high dose (DRUG).
Who is sponsoring clinical trial NCT01802515?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01802515's enrollment target sits among peer trials
14 1909th of 2000 higher than 90 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia